Virtual Library

Start Your Search

Ding Liu



Author of

  • +

    FP02 - Health Services Research/Health Economics (ID 120)

    • Event: WCLC 2020
    • Type: Posters (Featured)
    • Track: Health Services Research/Health Economics
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      FP02.09 - Effects of Chinese Reimbursement Policy on Molecular Diagnosis and Therapy of NSCLC from the Northern Part of Henan Province (ID 2441)

      00:00 - 00:00  |  Author(s): Ding Liu

      • Abstract
      • Presentation
      • Slides

      Introduction

      Gefitinib (Irisa) have significantly prolonged the overall survival of advanced non-small cell lung cancer (NSCLC) patients with the EGFR sensitivity mutations positive (EGFR+). Our hospital, the first affiliated hospital of Xinxiang Medical University, is the largest provincial Grade 3A hospital in northern part of Henan Province,most of the patients come from rural areas, and the incomes of the patients and their family members are too low to afford the expensive antitumor costs. Therefore, the expensive costs prevent the timely and sufficient treatment with gefitinib in patients with positive EGFR+ in our hospital. Fortunately, on September 2016, gefitinib was included in health care policy of Henan Province, thus the expenses were reduced significantly. The purpose of this study was to investigate the influence of China's reimbursement policy on molecular diagnosis and treatment of advanced lung adenocarcinoma(LUAD) in our hospital.

      Methods

      Here, the data of the LUAD from February 2015 to August 2016, as well as from September 2016 to March 2018 of our hospital were collected.

      The chi-square test is used to analysis: (1)the detection rate of EGFR gene mutations (EGFR-M) before and after reimbursement. (2)the detection rate of EGFR-M in the department of oncology before and after reimbursement respectively. (3) the detection rate of EGFR-M in the department of non-oncology before and after reimbursement respectively. (4)the application of EGFR-TKIs(including gefitinib and icotinib) in patients with EGFR+ before & after reimbursement.

      Results

      figure1.jpgIn this study, 315 cases and 405 cases were collected befor and after Semptember 2016 respectively:

      (1)The detection rate of EGFR-M was increased from 13.65% to 44.55% after reimbursement (P≤0.01) (Fig1A).

      (2)In the department of oncology, the detection rate of EGFR-M was elevated from 20.53% to 58.94% after reimbursement (P≤0.01).

      (3) In the department of non-oncology, the detection rate was also increased from 3.20% to 35% after reimbursement (P≤0.01).

      (4) The detection rate of EGFR-M was higher in the department of oncology than that of non-oncology department both before and after reimbursement (P≤0.01) (Fig1B & C).

      (5) After reimbursement, the application of EGFR-TKIs on patients with EGFR+ was increased prominently. There are only 21.74%(5/23) patients received treatment of EGFR-TKIs before September 2016, while most of patients with positive EGFR-sensitive mutations (72.55%, 74/102) were treated by EGFR-TKIs after September 2016(Fig1D) (P0.01).

      Conclusion

      Chinese reimbursement policy can affect the molecular analysis and therapy of NSCLC from the northern part of Henan province significantly.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.